Penumbra designs, develops, manufactures, and markets medical devices. The Company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies, aspiration based thrombectomy systems and accessory devices, and revascularization device for mechanical thrombectomy. It also provides neurovascular embolization coiling systems and neurovascular stents. In addition, the Company offers neurosurgical aspiration tools and detachable embolic coil systems and microcatheter devices.

Type
Public
HQ
Alameda, US
Founded
2004
Size (employees)
1,500 (est)
Penumbra was founded in 2004 and is headquartered in Alameda, US
Report incorrect company information

Penumbra Office Locations

Penumbra has offices in Sao Paulo, Darlinghurst, Berlin, Alameda and in 6 other locations
Alameda, US (HQ)
1321 Harbor Bay Parkway
Alameda, US
One Penumbra Place
Darlinghurst, AU
Suite 3, Level 5, 1 Oxford Street
Sao Paulo, BR
Royal Office Jardins Building, Suite 201 Avenida Brigadeiro Luis Antonio, 3421 Jardim Paulista
Berlin, DE
Am Borsigturm 44
Show all (12)
Report incorrect company information

Penumbra Financials and Metrics

Penumbra Revenue

Penumbra's revenue was reported to be $333.76 m in FY, 2017
USD

Revenue (Q1, 2018)

102.7 m

Gross profit (Q1, 2018)

66.6 m

Gross profit margin (Q1, 2018), %

64.8%

Net income (Q1, 2018)

5.5 m

EBIT (Q1, 2018)

4 m

Market capitalization (20-Jul-2018)

4.7 b

Closing share price (20-Jul-2018)

137.3

Cash (31-Mar-2018)

52.8 m
Penumbra's current market capitalization is $4.7 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

186.1 m263.3 m333.8 m

Revenue growth, %

41%

Cost of goods sold

62 m92.5 m116.6 m

Gross profit

124.1 m170.8 m217.1 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

50.4 m57.9 m65.1 m67.2 m73.2 m80.6 m102.7 m

Cost of goods sold

16.9 m18 m23.6 m24.3 m25.5 m29.7 m36.1 m

Gross profit

33.5 m39.9 m41.5 m42.9 m47.7 m50.9 m66.6 m

Gross profit Margin, %

66%69%64%64%65%63%65%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

19.5 m13.2 m50.6 m

Accounts Receivable

57.2 m47.7 m

Inventories

56.8 m73 m94.9 m

Current Assets

244.4 m263.8 m382.2 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

159.1 m17.6 m13.9 m15.9 m109.4 m76.6 m52.8 m

Inventories

50.3 m66.6 m68.4 m70.1 m79.2 m81.1 m94.6 m

Current Assets

249.1 m253.7 m260.3 m267.2 m372.4 m364.7 m387.9 m

PP&E

8.6 m9.7 m11.9 m16.2 m22.9 m24.4 m32 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

2.4 m14.8 m4.7 m

Depreciation and Amortization

1.8 m2.3 m3.8 m

Inventories

(25.1 m)(19.7 m)(18.8 m)

Accounts Payable

132 k1.4 m1.9 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

732 k780 k185 k(1.1 m)(3.1 m)5.5 m

Depreciation and Amortization

1.2 m1.4 m

Inventories

(18 m)66.6 m68.4 m70.1 m79.2 m208 k

Accounts Payable

1.5 m4 m4.1 m3.6 m5 m622 k
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Penumbra Online and Social Media Presence

Embed Graph
Report incorrect company information

Penumbra News and Updates

Thrombectomy Devices Market to be worth US$1,974.5 mn by 2022

The global thrombectomy devices market is estimated to be worth US$1,974.5 mn by 2022, considerably up from its evaluated worth of US$1,470.6 mn in 2017. Posted via Industry Today. Follow us on Twitter @IndustryToday

Neurovascular Devices Market will achieve moderate growth to cross $2.3 billion by 2024

Latin America, driven by Brazil neurovascular device market share, followed by Asia Pacific will witness fastest growth, estimated to be over 5.5%, due to higher prevalence rate of brain aneurysm. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Penumbra Company Life and Culture

Report incorrect company information